PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis

PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis

Background As an emerging treatment strategy for triple-negative breast cancer (TNBC), immunotherapy acts in part by inducing ferroptosis. Recent studies have shown that protein arginine methyltransferase 5 (PRMT5) has distinct roles in immunotherapy among multiple cancers by modulating the tumor mi...

Full description

Bibliographic Details
Main Authors: Jian Zhang, Bo Zhang, Ting Wang, Cheng Ji, Rui Ling, Zhe Wang, Qing Yao, Jie Duan, Jing Kong, Yaping Wang, Ge Zhao, Ruolei Li, Niuniu Hou, Juliang Zhang, Pengyu Fan, Liuyin Liu
Format: Article
Language:English
Published: BMJ Publishing Group 2023-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/6/e006890.full

Internet

https://jitc.bmj.com/content/11/6/e006890.full

Similar Items